Hepatitis A virus deletion mutants and vaccine formulations containing the same
AssigneeThe University of North Carolina at Chapel Hill
InventorsStanley M. Lemon, David R. Shaffer
Life of this patent
Estimating the term…
Abstract
Disclosed are live hepatitis A virus deletion mutants having a deletion mutation in the 5' nontranslated region of the viral genome. The deletion mutation may be selected from the group consisting of (a) pY1 deletion mutations that cause the virus to retain the ability to replicate in monkey kidney cells; and (b) deletion mutations between nucleotides 140 and 144 that render the virus temperature sensitive. Advantageously, the deletion mutation may be an attenuating mutation. Pharmaceutical formulations containing such viruses are disclosed, along with the use thereof to produce antibodies useful for diagnostic purposes and for imparting protective immunity against hepatitis A virus.
Claims10
A live hepatitis A virus deletion mutant having a deletion mutation in the 5' nontranslated region of the viral genome, wherein said deletion mutation is a pY1 deletion mutation that causes said virus to retain the ability to replicate in monkey kidney cells, and wherein said pY1 deletion mutation is selected from the goup consisting of:
- (a) .DELTA.99-134 deletion mutants;
- (b) .DELTA.96-134 deletion mutants;
- (c) .DELTA.96-137 deletion mutants:
- (d) .DELTA.96-139 deletion mutants, and
- (e) .DELTA.96-140 deletion mutants.
A method for inducing protective immunity against hepatitis A virus in a subject, comprising:
- administering to said subject an infectious, immunogenic, hepatitis A virus carrying an attenuating mutation, said virus being administered in an amount effective to induce protective immunity against hepatitis A virus, and said attenuating mutation being a deletion mutation in the 5' nontranslated region of the viral genome, wherein said deletion mutation is a pY1 deletion mutation that attenuates said virus, and wherein said pY1 deletion mutation is selected from the group consisting of:
- (a) .DELTA.99-134 deletion mutants;
- (b) .DELTA.96-134 deletion mutants;
- (c) .DELTA.96-137 deletion mutants;
- (d) .DELTA.96-139 deletion mutants, and
- (e) .DELTA.96-140 deletion mutants.
A vaccine formulation useful for inducing protective immunity against hepatitis A virus, comprising, in a pharmaceutically acceptable carrier, an infectious, immunogenic, hepatitis A virus carrying an attenuating mutation in an amount effective to induce protective immunity against hepatitis A virus, said attenuating mutation being a deletion mutation in the 5' nontranslated region of the viral genome that is a pY1 deletion mutation that attenuates said virus, wherein said pY1 deletion mutation is selected from the group consisting of:
- (a) .DELTA.99-134 deletion mutants;
- (b) .DELTA.96-134 deletion mutants;
- (c) .DELTA.96-137 deletion mutants;
- (d) .DELTA.96-139 deletion mutants;
- and
- (e) .DELTA.96-140 deletion mutants.
Dependencies are inferred from the claim text.